ClinicalTrials.gg
RecruitingNCT07488806Updated Mar 23, 2026

Natural History Study for Patients With Nemaline Myopathy in Spain

An observational study in Nemaline Myopathy, Myopathies and Myopathic Conditions, sponsored by Hospital Universitari Vall d'Hebron Research Institute. Recruiting at 1 site in Spain. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Hospital Universitari Vall d'Hebron Research Institute · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Muscular Diseases with a site in Spain — 10 open to participants now, 12 under way, 3 of them phase 3. Muscular Diseases · Spain.

Started
2026
with 3 others
Observational
7 of 24
2 open now
Primary completion
2031-06
later than 10 of 11 live
Registered
21st of 24
by date

Among the 24 studies in Muscular Diseases with a site in Spain, this one is one of 4 that started in 2026, is one of 7 observational ones, reaches primary completion later than 10 of the 11 other live ones, and was the 21st registered.

Muscular Diseases

232 studies on the registry are indexed under Muscular Diseases; 54 are open to participants now.

Browse Muscular Diseases studies →

Open to participants now

10 of the 24 studies in Muscular Diseases with a site in Spain are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 38 Muscular Diseases studies recruiting now, 21 (55%) set no upper age limit and 10 (26%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Muscular Diseases with a site in Spain, or all of them as a file.
02

Study summary

The objective of this natural history study is to comprehensively characterize the disease progression and clinical features of nemaline myopathies. The study aims to establish a well-defined cohort of patients in Spain, enabling long-term follow-up and facilitating recruitment for future clinical trials.

Read the detailed description

The aims of the study are:

  • Identify the specific genes and mutations responsible for NM in Spain.
  • Define the in-depth phenotyping of NM and the phenotype-genotype relationship.
  • Characterize the natural history of NM through the systematic collection of clinical (retrospective and prospective data), functional, and respiratory data in diagnosed patients in order to:

    • Describe the progression of the disease without disease-modifying therapies.
    • Identify reliable biomarkers and outcome measures for future clinical trials.
    • Align the national protocol with international efforts to generate comparable data.
03

Conditions studied

  • Nemaline Myopathy
  • Myopathies
  • Myopathic Conditions
  • NEB
  • ACTA1
  • TPM2
  • TPM3
  • TNNT1
  • CFL2
  • KBTBD13
  • KLHL40
  • KLHL41
  • LMOD3
  • Cohort Studies
  • MYPN
  • TNNT3

Browse trials for

Keywords

  • NATURAL HISTORY
  • NEMALINE MYOPATHY
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a confirmed clinical and genetic diagnosis of MN (mutations in ACTA1, NEB, TPM2, TPM3, KBTBD13, CFL2, KLHL40, KLHL41, LMOD3, MYPN, TNNT1, TNNT3), or under discussion if they only have a compatible biopsy.

Eligibility criteria

Inclusion Criteria:

  • Patients with a confirmed clinical and genetic diagnosis of MN (mutations in ACTA1, NEB, TPM2, TPM3, KBTBD13, CFL2, KLHL40, KLHL41, LMOD3, MYPN, TNNT1, TNNT3), or under discussion if they only have a compatible .
  • Signed by the patient or Legal Authority Responsible, and/or assent by the subject (in pediatric population).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • All patients

    Patients with a confirmed clinical and genetic diagnosis of MN (mutations in ACTA1, NEB, TPM2, TPM3, KBTBD13, CFL2, KLHL40, KLHL41, LMOD3, MYPN, TNNT1, TNNT3), or under discussion if they only have a compatible biopsy

    Diagnostic Test: Muscle Ultrasound · Diagnostic Test: Motor function scales · Other: Complete physical examination · Other: Ventilatory/ respiratory, Cardiac and other support assessment · Other: QOL assessment, Neuropsychological · Device: Digital Biomarkers · Other: Oromotor function and nutrition · Other: Motor Milestone Assessments

Interventions

  • Diagnostic testMuscle Ultrasound

    Ultrasound guided evaluation of 28 muscles evaluated accross different body regions, assessed using the Heckmatt gradinf system (semiquantitative scale).

  • Diagnostic testMotor function scales

    Evaluation of patients motor function using motor scales (CHOP-INTEND, MFM32, HINE-2, NSAA, PDSM-3, RFF, 10m walk, PUL)

  • OtherComplete physical examination

    Complete physical evaluations including muscle power and goniometry measurements

  • OtherVentilatory/ respiratory, Cardiac and other support assessment

    Assessment of ventilatory, cardiac, nutritional, and other support needs

  • OtherQOL assessment, Neuropsychological

    Assessment of quality of life

  • DeviceDigital Biomarkers

    Video/photos with the aim is to record actions such as lifting a glass, raising arms above the head, getting up from the floor or a chair, walking, or running, in order to later analyze in detail how these movements are performed.

  • OtherOromotor function and nutrition

    Assessment of bulbar funcionality: feeding devices, nutritional status.

  • OtherMotor Milestone Assessments

    Motor milestones age of acquisition and loss (if applicable)

06

What researchers measure

Primary outcomes

  1. Observe changes in muscle echogenicity by muscle ultrasound.

    A standardized muscle ultrasound protocol of assessment is performed (whole body). Muscle images are scored using the Heckmatt scale (score 1-4): * Heckmatt grade 1 represents a normal muscle image. * Heckmatt grade 2 shows an increased echogenicity without attenuation of the deeper image regions. * Heckmatt grade 3 indicates a larger increase in echogenicity with some visible loss of normal muscle architecture. * Heckmatt grade 4 shows a strongly increased echogenicity with complete loss of recognizable muscle architecture.

    Time frame: Change from baseline through study completion, an average of 5 years

  2. Observe natural history changes in motor function using the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)

    The CHOP-INTEND assesses a child's ability to move their body in a lying down position, supported sitting, and assisted rolling through 16 items. Scores range from 0 to 64, with higher scores indicating better motor function. Change in motor function assessed using age-appropriate validated motor scales and dependent on patient's ability.

    Time frame: Change from baseline through study completion, an average of 5 years

  3. Observe natural history changes in motor function using the Hammersmith Infant Neurological Examination Section 2 (HINE-2)

    This is a 37-item measure of infant developmental motor milestones that will be performed in participants aged 0-24months. Scores are interpreted in relation to optimality scores and cut-off scores for the participant's age. Higher scores represented higher function.

    Time frame: Change from baseline through study completion, an average of 5 years

  4. Observe natural history changes in Peabody Developmental Motor Scales (PDMS-3) Scale Score

    Change in motor function assessed using age-appropriate validated motor scales and dependent on patient's ability. PDMS-3 measures various motor abilities in young children. Four types of normative scores are yielded: age equivalents, percentile ranks, subtest scaled scores, and composite index scores. Higher scores indicate higher level of function.

    Time frame: Change from baseline through study completion, an average of 5 years

  5. Observe natural history changes in motor function using the Motor Function Measure (MFM32) Scale Score

    Change in motor function assessed using age-appropriate validated motor scales and dependent on patient's ability. This motor function assessment consists of 32 items organized in three dimensions: standing position and transfers, axial and limb proximal motor function, and limb distal motor function. Total scores are given between 0-100, with 0 indicating severe functional impairment and 100 indicating no functional impairment.

    Time frame: Change from baseline through study completion, an average of 5 years

  6. Observe natural history changes in motor function using the North Star Ambulatory Assessment (NSAA) score

    Change in motor function assessed using age-appropriate validated motor scales and dependent on patient's ability. Scores in the NSAA scale range from 0 to 34, with higher scores indicating better motor function.

    Time frame: Change from baseline through study completion, an average of 5 years

  7. Observe natural history changes in the Performance of Upper Limb (PUL) score

    Change in upper limb function assessed using the Performance of Upper Limb (PUL) scale. Higher scores indicate better function.

    Time frame: Change from baseline through study completion, an average of 5 years

Secondary outcomes

  1. Observe the natural clinical progression in respiratory function.

    Respiratory function will be assessed longitudinally using age-appropriate measures depending on patient ability. Respiratory status will include ventilatory support requirements (none, non-invasive ventilation, or invasive ventilation) and time on/off ventilator, when feasible. Forced vital capacity (FVC), expressed as percent predicted for age and sex, will be used when spirometry is possible.

    Time frame: Change from baseline through study completion, an average of 5 years

  2. Observe changes in Nutritional Status

    Assessment of nutritional status over time through indicators such as feeding method (oral versus enteral feeding) and need for nutritional support. Swallowing status and dietary modifications will be recorded when applicable. Changes from baseline will be analyzed to evaluate nutritional progression and feeding outcomes.

    Time frame: Change from baseline through study completion, an average of 5 years

  3. Observe changes in Quality of Life

    Assessment of patient or caregiver-reported quality of life using validated questionnaires appropriate for age and functional status, including standardized health-related quality of life instruments (the Clinical Global Impression-Severity \[CGI-S\], the Clinical Global Impression-Change \[CGI-C\], Patient Global Impression of Change \[PGI-C\], and Patient Global Impression of Severity \[PGI-S\]). Total scores and domain-specific scores will be analyzed. Changes from baseline will be evaluated to assess perceived health status and daily functioning.

    Time frame: Change from baseline through study completion, an average of 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2031, 60 months later.

Of 36 observational studies under Muscular Diseases, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 159. This study's planned 60 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 23, 2026
StartEst.
Jun 2026
Primary completionEst.
Jun 2031
CompletionEst.
Jun 2032
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07488806
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jun 2031 (estimated)
Completion
Jun 2032 (estimated)
Last update
Mar 23, 2026

Study contacts

Laura Costa-Comellas, M.D.
Contact
laura.costacomellas@vallhebron.cat
+34677255332

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion